The US FDA has approved Tidepool Loop, an app designed to automate insulin dosing. Born out the do-it-yourself, “we are not waiting” movement, it has designs and features not in the first wave of commercial automated systems like Omnipod 5 and Tandem’s Control IQ. CEO Howard Look talks to Stacey about what was approved here…
Right now, the very first diabetes technology with roots in the do-it-yourself community is in front of the FDA. Tidepool CEO Howard Look joins us to talk about what, if approved, will be a prescription mobile app controller: Tidepool Loop. We get details on the submission, including everything from how you’d actually get this app…
Loop – the DIY app that helps with automated insulin delivery – may become the first do it yourself diabetes solution to go to the FDA. But why did Tidepool decide to take on this challenge? Stacey talks to Tidepool CEO Howard Look about what this decision means, how it’s going to work and what it means…
Howard Look formed Tidepool after his daughter was diagnosed with type 1 in 2011 and, as a self-described “geek-dad” he was frustrated with the lack of access to her diabetes data. Tidepool is a platform for diabetes information and the apps that use it. It includes an uploader to get information off of devices like…
Anticipation just keeps growing for the new Omnipod system, still waiting for FDA approval. This week, we talk to Dr. Trang Ly, Senior Vice President & Medical Director at Insulet Corporation. We’ll get an in-depth run through of the features of Omnipod 5 with Horizon, what makes it different from the other hybrid closed loops…
Tandem Diabetes has made some big moves recently, acquiring two new companies – one makes infusion sets, the other a patch pump called Sigi, and their tiny Mobi pump is in front of the FDA right now. We’re finding out how it may all come together from Tandem’s EVP and Chief Strategy Office Elizabeth Gasser.…
It’s In the News, a look at the top stories and headlines from the diabetes community happening now. This week, Dexcom sets a US release date for the G7, we find out whether Tandem will be a Tidepool Loop partner now that Insulet and Medtronic are out, Omnipod Eros to be discontinued, a new study…
Top stories in this news this week: Stem cell research Vertex company buys Viacyte, another company looking at stem cells for a functional cure for T1D, some tslim users are getting access to Tandem’s new mobile bolus feature, One Drop shows a “health sensor” on its website, a study shows that screening for type 1…
We are very excited to catch up with the folks from Beta Bionics! Their fully automated bionic pancreas is called the iLet. They are getting closer to submitting to the US FDA and were able to give us an update on some of the most anticipated features. Kate Farnsworth is a consultant for Beta Bionics…
[podcast src=”https://html5-player.libsyn.com/embed/episode/id/18851828/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/3e9ccc/” width=”100%” scrolling=”no” class=”podcast-class” frameborder=”0″ placement=”top” primary_content_url=”http://traffic.libsyn.com/diabetesconnections/Ep_373_Final_Ben_West.mp3″ libsyn_item_id=”18851828″ height=”90″ theme=”custom” custom_color=”3e9ccc” player_use_thumbnail=”use_thumbnail” use_download_link=”use_download_link” download_link_text=”Download” /] Ben West was a key organizer and architect of Nightscout and OpenAPS software. Even after all of the DIY and commercial development of the last ten years, he says we’ve barely scratched the surface of removing the mental and…